These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 15987767)

  • 21. Evidence for direct physical association between a K+ channel (Kir6.2) and an ATP-binding cassette protein (SUR1) which affects cellular distribution and kinetic behavior of an ATP-sensitive K+ channel.
    Lorenz E; Alekseev AE; Krapivinsky GB; Carrasco AJ; Clapham DE; Terzic A
    Mol Cell Biol; 1998 Mar; 18(3):1652-9. PubMed ID: 9488482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ATP activates ATP-sensitive potassium channels composed of mutant sulfonylurea receptor 1 and Kir6.2 with diminished PIP2 sensitivity.
    Pratt EB; Shyng SL
    Channels (Austin); 2011; 5(4):314-9. PubMed ID: 21654216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The structure and function of the ATP-sensitive K+ channel in insulin-secreting pancreatic beta-cells.
    Miki T; Nagashima K; Seino S
    J Mol Endocrinol; 1999 Apr; 22(2):113-23. PubMed ID: 10194514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels.
    Hansen AM; Hansen JB; Carr RD; Ashcroft FM; Wahl P
    Br J Pharmacol; 2005 Feb; 144(4):551-7. PubMed ID: 15678092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An abundant, truncated human sulfonylurea receptor 1 splice variant has prodiabetic properties and impairs sulfonylurea action.
    Schmid D; Stolzlechner M; Sorgner A; Bentele C; Assinger A; Chiba P; Moeslinger T
    Cell Mol Life Sci; 2012 Jan; 69(1):129-48. PubMed ID: 21671119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of the trafficking efficiency and functional properties of ATP-sensitive potassium channels through a single amino acid in the sulfonylurea receptor.
    Cartier EA; Shen S; Shyng SL
    J Biol Chem; 2003 Feb; 278(9):7081-90. PubMed ID: 12496311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes.
    Proks P; Arnold AL; Bruining J; Girard C; Flanagan SE; Larkin B; Colclough K; Hattersley AT; Ashcroft FM; Ellard S
    Hum Mol Genet; 2006 Jun; 15(11):1793-800. PubMed ID: 16613899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On potential interactions between non-selective cation channel TRPM4 and sulfonylurea receptor SUR1.
    Sala-Rabanal M; Wang S; Nichols CG
    J Biol Chem; 2012 Mar; 287(12):8746-56. PubMed ID: 22291026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.
    Sunaga Y; Gonoi T; Shibasaki T; Ichikawa K; Kusama H; Yano H; Seino S
    Eur J Pharmacol; 2001 Nov; 431(1):119-25. PubMed ID: 11716850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carriers of an inactivating beta-cell ATP-sensitive K(+) channel mutation have normal glucose tolerance and insulin sensitivity and appropriate insulin secretion.
    Huopio H; Vauhkonen I; Komulainen J; Niskanen L; Otonkoski T; Laakso M
    Diabetes Care; 2002 Jan; 25(1):101-6. PubMed ID: 11772909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of K(ATP)-channels in rat basilar and middle cerebral arteries: studies of vasomotor responses and mRNA expression.
    Jansen-Olesen I; Mortensen CH; El-Bariaki N; Ploug KB
    Eur J Pharmacol; 2005 Oct; 523(1-3):109-18. PubMed ID: 16226739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Congenital hyperinsulinism associated ABCC8 mutations that cause defective trafficking of ATP-sensitive K+ channels: identification and rescue.
    Yan FF; Lin YW; MacMullen C; Ganguly A; Stanley CA; Shyng SL
    Diabetes; 2007 Sep; 56(9):2339-48. PubMed ID: 17575084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 2-(4-Methoxyphenoxy)-5-nitro-N-(4-sulfamoylphenyl)benzamide activates Kir6.2/SUR1 K(ATP) channels.
    Nielsen FE; Jacobsen P; Worsaae A; Arkhammar PO; Wahl P; Bondo Hansen J
    Bioorg Med Chem Lett; 2004 Dec; 14(23):5727-30. PubMed ID: 15501029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands.
    Winkler M; Stephan D; Bieger S; Kühner P; Wolff F; Quast U
    J Pharmacol Exp Ther; 2007 Aug; 322(2):701-8. PubMed ID: 17495126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diverse roles of K(ATP) channels learned from Kir6.2 genetically engineered mice.
    Seino S; Iwanaga T; Nagashima K; Miki T
    Diabetes; 2000 Mar; 49(3):311-8. PubMed ID: 10868950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different molecular sites of action for the KATP channel inhibitors, PNU-99963 and PNU-37883A.
    Cui Y; Tinker A; Clapp LH
    Br J Pharmacol; 2003 May; 139(1):122-8. PubMed ID: 12746230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent and selective activation of the pancreatic beta-cell type K(ATP) channel by two novel diazoxide analogues.
    Dabrowski M; Larsen T; Ashcroft FM; Bondo Hansen J; Wahl P
    Diabetologia; 2003 Oct; 46(10):1375-82. PubMed ID: 12961066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uncoupling by (--)-epigallocatechin-3-gallate of ATP-sensitive potassium channels from phosphatidylinositol polyphosphates and ATP.
    Jin JY; Park SH; Bae JH; Cho HC; Lim JG; Park WS; Han J; Lee JH; Song DK
    Pharmacol Res; 2007 Sep; 56(3):237-47. PubMed ID: 17656102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remodelling of the SUR-Kir6.2 interface of the KATP channel upon ATP binding revealed by the conformational blocker rhodamine 123.
    Hosy E; Dérand R; Revilloud J; Vivaudou M
    J Physiol; 2007 Jul; 582(Pt 1):27-39. PubMed ID: 17510180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity.
    Kawaki J; Nagashima K; Tanaka J; Miki T; Miyazaki M; Gonoi T; Mitsuhashi N; Nakajima N; Iwanaga T; Yano H; Seino S
    Diabetes; 1999 Oct; 48(10):2001-6. PubMed ID: 10512365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.